MAP2K7 and metastatic melanoma: Three combinations of BRAF and MEK inhibitors have been approved by the US FDA for metastatic melanoma with BRAF V600E or V600K mutations: cobimetinib plus vemurafenib, dabrafenib plus trametinib, and encorafenib plus binimetinib.278, 281